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Abstract
SPLUNC1 is an abundantly secreted innate immune protein in the mammalian respiratory tract 
that exerts bacteriostatic and antibiofilm effects, binds to lipopolysaccharide (LPS), and acts as a 
fluid-spreading surfactant. Here, we unravel the structural elements essential for the surfactant and 
antimicrobial functions of human SPLUNC1 (Short Palate Lung Nasal Epithelial Clone 1). A 
unique α-helix (α4) that extends from the body of SPLUNC1 is required for the bacteriostatic, 
surfactant, and LPS-binding activities of this protein. Indeed, we find that mutation of just four 
leucine residues within this helical motif to alanine is sufficient to significantly reduce the fluid 
spreading abilities of SPLUNC1, as well as its bacteriostatic actions against the Gram-negative 
pathogens Burkholderia cenocepacia and Pseudomonas aeruginosa. Conformational flexibility in 
the body of the SPLUNC1 is also involved in the bacteriostatic, surfactant, and LPS-binding 
functions of the protein as revealed by disulfide mutants introduced into SPLUNC1. In addition, 
SPLUNC1 exerts antibiofilm effects against Gram-negative bacteria, although α4 is not involved 
in this activity. Interestingly, though, the introduction of surface electrostatic mutations away from 
α4 based on the unique dolphin SPLUNC1 sequence, and confirmed by crystal structure, are 
shown to impart antibiofilm activity against Staphylococcus aureus, the first SPLUNC1-depenent 
effect against a Gram-positive bacterium reported to date. Together, these data pinpoint SPLUNC1 
structural motifs required for the antimicrobial and surfactant actions of this protective human 
protein.
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Human Short Palate Lung Nasal Epithelial Clone 1 (SPLUNC1) is a 256-residue protein 
member of the PLUNC family that includes SPLUNCs 1–3 and LPLUNCs 1–5. 1 
SPLUNC1, also called BPIFA1, is expressed in upper airways of the lungs, where it is one 
of the most abundantly secreted proteins, as well as in the colon and kidneys, and has 
established roles in several aspects of pulmonary function and innate immunity. 2–4 It 
regulates the volume of airway surface liquid that covers the pulmonary epithelia by 
inhibiting the actions of the epithelial sodium channel (ENaC), which is responsible for 
transepithelial movement of sodium and water. In the context of cystic fibrosis (CF) 
inactivating mutations of the CFTR channel, ENaC’s actions exacerbate the dehydration of 
CF pulmonary tissues. 5 Eighteen amino acids in the N-terminal region of SPLUNC1 (S18) 
were found to be necessary and sufficient for regulating ENaC in normal conditions in vitro; 
however, in the low pH of CF tissues, both S18 and the body of SPLUNC1 were required to 
control ENaC. 6 SPLUNC1 has also been shown to act as a surfactant to spread fluids at the 
air-water interface, and an innate antibacterial factor against Gram-negative bacterial 
pathogens. 7–15 For example, SPLUNC1 was demonstrated to reduce Mycoplasma 
pneumoniae and Klebsiella pneumoniae infections in mouse models, and to prevent the 
growth of Pseudomonas aeruginosa both in vitro and in vivo. 13,16–21 The protein was also 
reported to associate with lipopolysaccharides (LPS) from E. coli and P. aeruginosa, albeit 
through unknown mechanisms. 7,18,22–25 To date, while SPLUNC1’s structural mechanism 
in regulating ENaC is relatively well understood, the structural basis of SPLUNC1’s actions 
as a surfactant and antibacterial factor have remained less clear.
The crystal structure of human SPLUNC1 was first reported in 2013, and by a second group 
in 2014, and both reveal a “super-roll” fold composed of a curved β-sheet flanked by α-
helices that together enclose a hydrophobic core consisting largely of leucine residues 
(Figures 1A, B). 6,25 The 2013 report focused on the role the body of SPLUNC1 played in 
presenting the S18 peptide, which is disordered in all reported structures, for ENaC 
inhibition in both normal and CF tissues in vitro. By contrast, the 2014 report highlighted 
the ability of SPLUNC1 to associate in vitro with lipids of established pulmonary functions, 
specifically dipalmitoylphosphatidylcholine (DPPC). While SPLUNC1 shares structural 
similarity to two human innate protein proteins, the lipopolysaccharide binding protein 
(LBP) and bacteriocidal permeability-increasing protein (BPI), which are twice the size of 
SPLUNC1, its closest structural homologs are equine latherin and the dust mite allergen 
derP7 which are roughly SPLUNC1’s size. 3,26 Latherin is an established surfactant that 
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spreads fluid over the animal’s pelt for cooling. 27 The NMR structure of equine latherin was 
reported in 2013 and shares 3.9 Å rmsd over 172 equivalent Cα positions and 27% sequence 
identity with human SPLUNC1. DerP7, an allergen of the Dermatophagoides pteronyssinus 
European house dust mite, shares 3.4 Å rmsd over 147 equivalent Cα positions and only 5% 
sequence identity with human SPLUNC1. In addition to their similarity in overall fold, 
SPLUNC1, latherin and derP7 all contain leucine- or isoleucine-rich loops that extend from 
the body of each protein. In SPLUNC1, this forms α-helix 4 (α4), while in latherin and 
derP7 they form relatively long and short loops, respectively, with at least four Leu or Ile 
residues (Figures 1C, 1D). An elegant model for the surfactant actions of latherin has been 
proposed wherein this Leu-rich loop seeds the unrolling of the protein’s super-roll fold to 
expose its Leu-rich hydrophobic core at the air-water interface. 28,29 Here, we test this 
hypothesis for human SPLUNC1, and in doing so also address the structural basis of its 
ability to act as an LPS-binding and innate antibacterial factor. Together, the data presented 
support the conclusion that improved SPLUNC1s could be designed to act as highly 
effective protective factors of potential use in the diseased lungs of patients with CF or other 
pulmonary disorders.
EXPERIMENTAL PROCEDURES
Protein Mutagenesis, Expression and Purification
Protein mutagenesis, expression and purification were carried out as previously described. 6 
In addition to our previous protocol, Rosetta-gami 2 competent cells (EMD Millipore, MA, 
USA) were used and ion exchange chromatography was included for pDest566 (MBP Derp7 
fusion) following the first Ni-NTA His-Trap gravity column purification. Both His-tagged 
and non-His-tagged proteins were examined and gave similar results. pDest566 was a gift 
from Lars Pedersen (NIEHS) and pET32-sLatherin (Thioredoxin Latherin fusion) gift from 
Brian Smith (University of Glasgow). Curosurf was purchased from Chiesi USA, Inc (Cary, 
NC). Lysozyme was purchased from MP Biochemicals, LLC. Fatty acid free BSA purchased 
from Sigma.
Protein Surfactant and Stability Properties
Air-liquid equilibrium surface tension measurements were performed using the Wilhelmy 
plate method, with a Sigma 701 force tensiometer (Biolin Scientific, Stockholm Sweden). 
Samples measured were at 2uM in 50mM Hepes, pH 8.0 and 150mM NaCl. Briefly, 20 ml 
of sample was measured every minute for 25 minutes at room temperature using a flame-
cleaned platinum plate. Static contact angles were measured using a KSV Instruments LCD 
CAM 200 optical contact angle meter at room temperature. All measurements were carried 
out with drops dispensed from a Hamilton 500ul glass syringe (Hamilton CO, Reno NV) 
onto Parafilm (Bemis, Oshkosh WI).
Protein stability was determined using the Circular Dichroism method. 30 10uM of 
rSPLUNC1 wt and mutant proteins in CD buffer containing 10mM potassium phosphate 
(pH 7.4), 100mM potassium fluoride and +/− 5 mM DTT were loaded into a 1-mm cuvette. 
Using a Chirascan-plus instrument (Applied Photophysis Limited), spectra from 185 to 280 
nM were recorded at 20 ± 1.0 °C. Measurements were corrected for background signal using 
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a CD buffer sample. The melting profile of the sample was monitored at 221 nM from 20 °C 
to 94 °C.
Protein Crystallization and Structure Determination
Crystals of purified rhSplunc1 disulfide bond mutants were grown at 37 °C in 6M 
ammonium nitrate, and 0.1M Tris-HCL (pH 8.5), and cryoprotected in this condition with 
15% glycerol. Crystals were flash-frozen in liquid nitrogen in preparation for X-ray data 
collection. Diffraction data were collected on the 23-ID beamline at GM/CA-CAT 
(Advanced Photon Source, Argonne National Laboratory). Data were processed using 
standard methods and structures determined by molecular replacement using the rhSplunc1 
structure as a search model (PDB:4KGH). 31–33 Structures were refined using standard 
methods. Coordinates and structure factors can be found at PDB: 517J, 517K and 517L
Primary Human Bronchial Epithelial Cultures (HBEC)
HBECs were obtained and harvested from freshly excised bronchial specimens from normal 
subjects (n = 4–5 donors) following the protocol approved by the University of North 
Carolina Institutional Review Board. 34 HBECs were cultured at an air-liquid interface in a 
modified bronchial epithelial growth medium with 5% CO2 at 37°C and were used 3–4 
weeks after the seeding on 12-mm T-clear inserts (Corning-Costar, Corning, NY, USA). 
During image acquisition, HBECs were maintained in a modified Ringer Solution as 
described previously. 35
Confocal Microscopy Measurement and Analysis of ASL
ASL labeling with Dextran-tetramethylrodamine (Life Technologies, D-1817) was 
performed as described previously. 6,35 Acquiring ASL images using a Leica SP8 confocal 
microscope with a 63x/1.3 Numerical Aperture glycerol immersion lens and analyzing 
acquired ASL images were performed as described previously. 36
Bacterial Growth and Biofilm Assays
B. cenocepacia J2315 (obtained from Dr. John J. Lipuma, CFF Burkholderia cepacia 
Research Laboratory and Repository, University of Michigan Medical School), P. 
aeruginosa, and S. aureus (obtained from Dr. Matthew Wolfgang, University of North 
Carolina at Chapel Hill) were grown in Luria broth (LB) at 37°C for 24 h with shaking 300 
rpm. CFU/ml were determined by serial dilution plating on LB agar plates. The bacterial 
cultures were adjusted to an optical density at 600 nm (OD600) of ~ 0.600, and 106 CFU/ml 
bacteria was co-incubated with varying concentrations of rSPLUNC1 wt and mutant 
proteins in flat bottom 96-well plates (Corning Incorporated) for 24 h at 37°C. For 
antimicrobial activity, bacterial growth was measured at 24 h at OD600 nm. Samples were 
collected at 24 h, serial diluted in Ringer’s solution and plated on LB agar plates to 
determine the number of CFU per milliliter. For antibiofilm activity, plates were washed and 
biofilms were fixed with methanol and stained with 1% crystal violet. After rinsing with 
distilled water, the stained biofilms were resolubilized with 33% acetic acid. Biofilm 
formation was measured at OD590 nm.
Walton et al. Page 4
Biochemistry. Author manuscript; available in PMC 2016 June 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
LPS Binding Assays
A modified, enzyme-linked immunosorbent assay (ELISA)-based LPS binding method was 
used to detect interaction between LPS and SPLUNC1 as described previously. 23 Briefly, a 
96-well plate was coated overnight with purified LPS (400 ng/well) from Pseudomonas 
aeruginosa 10 or Escherichia coli 055:B5 (Sigma, St. Louis, MO). Wells were washed and 
blocked with 1% bovine serum albumin (BSA)–phosphate-buffered saline (PBS) for 1 h; 
then, 2-fold dilutions of purified SPLUNC1 (400 ng) were added to each well in duplicate. 
PBS was used as a control for this experiment. An antibody specific to human SPLUNC1 
(Hycult, Plymouth Meeting, PA) was used to detect the LPS-bound SPLUNC1. After the 
secondary antibody reaction performed using horseradish peroxidase (HRP)-conjugated 
anti-mouse IgG, enzyme activity was detected using a TMB Ultra 1-step assay (Pierce 
Biotechnology, Inc., Rockford, IL). Absorbance was detected at OD450 nm in a BioTek 
spectrophotometer (BioTek, Winooski, VT). This experiment was performed three times, 
and the data were presented as means ± SD.
RESULTS
Human SPLUNC1 is a Strong Protein Surfactant
The ability of human SPLUNC1 to act as a surfactant was examined using the Wilhelmy 
plate method. Purified human SPLUNC1 at 2 μM (50 μg/mL) in 50 mM HEPES pH 8.0 
buffer with 150 mM NaCl exhibited a surface tension of 38 mN/m (Figure 2A; Table 1). 
Water and buffer (50 mM HEPES pH 8.0 buffer with 150 mM NaCl) demonstrated a surface 
tension of 72 mN/m, which is standard for solutions lacking surfactants. Lysozyme at 2 μM 
(45 μg/mL) also exhibited a surface tension of 72 mN/m, indicative of a lack of surfactant 
activity for this protein, while BSA at 2 μM (133 μg/mL) exhibited a moderate ability to act 
as a surfactant, reducing surface tension to 56 mN/m. Two structural homologues of 
SPLUNC1, the equine pelt cooling factor Latherin 28 and the dust mite allergen derP7 29, 
were also tested at 2 μM and exhibited moderate surfactant actions, reducing surface tension 
to 52 mN/m and 55 nM/m, respectively. The pulmonary surfactant Curosurf, a mixture of 
lipid purified from porcine lungs and employed clinically to treat respiratory distress, was 
tested at 1.5 mg/mL and reduced surface tension to 32 mN/m. 37 However, Curosurf at the 
same mass to volume ratio as SPLUNC1, 50 μg/mL, reduced surface tension to only 52 
mN/m. Thus, human SPLUNC1 is a strong protein-only surfactant and is superior to two 
proteins, latherin and DerP7, that share a common fold. Furthermore, SPLUNC1’s surfactant 
activities are on-par with that of the standard of care for respiratory distress, even when 
employed at 30-fold less concentration on a weight per volume basis.
SPLUNC1’s α4 is Critical to Surfactant Activity
To determine the molecular basis of SPLUNC1’s surfactant activity, we designed several 
mutant forms of the protein using the human SPLUNC1 crystal structure (see Table 1 for 
SPLUNC1 proteins examined), and tested their ability to reduce surface tension. All variant 
proteins were expressed and purified as described, and were found using circular dichroism 
(CD) and CD-monitored thermal denaturation to be similar to wild-type SPLUNC1 in terms 
of overall structure and stability (e.g., see below). 30 First, eliminating SPLUNC1’s ENaC 
inhibitory domain (the S18 region) did not alter the surfactant activity of SPLUNC1 (ΔS18, 
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Figure 2B; all proteins are at 2 μM; Table 1). Second, it has been hypothesized that a 
surface-exposed leucine-rich loop in equine Latherin would be critical to surfactant 
activity. 28 In human SPLUNC1, that region corresponds to α4 (see Figs. 1C–D). Thus, we 
created a form of SPLUNC1 lacking α4 (Δα4) and found that this variant exhibited 
significantly diminished surfactant activity, only reducing surface tension to 47 mN/m 
(SPLUNC1Δα4 in Figure 2B). Thus, α4 in SPLUNC1 is crucial to the surfactant actions of 
human SPLUNC1.
Leucines in and around SPLUNC1’s α4 are conserved and present in the structural 
homologs Latherin and derP7 (Fig. 1; Table 1). We mutated four leucines in that region 
(L87, L88, L91, L92) simultaneously to alanines (LAx4) and to serines (LSx4; see Fig. 1B) 
in SPLUNC1. We found that these proteins each showed the same diminishment of 
surfactant activity as Δα4, reducing surface tension to only 46–47 mN/m (Figure 2B). A 
control mutant in which five surface-exposed leucines (L191, L192, L195, L203, L204) 
located away from α4 on human SPLUNC1 were mutated to alanine (LAx5; Table 1; see 
Fig. 1B) did not show an impact on its surfactant activity, reducing surface tension to the 
wild-type level of 38 mN/m in the Wilhelmy plate assay. Thus, the leucines in the α4 region 
are necessary for the surfactant activities of human SPLUNC1.
We employed contact angle measurements of SPLUNC1 and specific variants (Figure 2C; 
all proteins at 2 μM) as a secondary assessment of surfactant activity. Contact angles below 
90° are considered to be “wetting” and to be indicative of surfactant activity (the spreading 
of fluid across a surface), while those above 90° are “non-wetting”. Human SPLUNC1 
exhibited a contact angle of 86°, similar to that observed for SPLUNC1 ΔS18 and LAx5 
(Figure 2C). By contrast, SPLUNC1 Δα4 and LAα4 both exhibited significantly higher 
contact angles of 93° and 96°, respectively (Figure 2C), similar to that observed for the weak 
surfactant protein BSA (94°). By this measure, SPLUNC1, ΔS18, and LAx5 can be 
categorized as wetting with intact surfactant abilities, while SPLUNC1 Δα4 and LAα4 are 
relatively non-wetting with reduced surfactant actions. These data are similar to those 
obtained in the Wilhelmy plate assay, and support the conclusion that α4 and the leucines 
therein are crucial to SPLUNC1’s surface tension lowering activities.
Designed Disulfide Bonds Reduce SPLUNC1’s Surfactant Activity
SPLUNC1 is composed of a “super-roll” fold formed by relatively parallel α-helices that 
come together adjacent to a rolled β-sheet (see Fig. 1A) to create a hydrophobic core 
composed largely of leucine residues. Therefore, it has been hypothesized that such proteins 
act as surfactants by partially or completely unrolling at the helical interface (grey dotted 
line in Fig. 1B) to expose their internal leucines to the air. 28 To test this hypothesis, we 
generated mutant forms of human SPLUNC1 in which disulfide bonds were added to the 
interface between α5 and α-helices 1-3. The addition of disulfides requires specific 
proximities for the amino acids to be mutated; thus, we chose two sets of residues expected 
to place newly-introduced cysteines close enough to form disulfide bonds. M3 (I76C
+V214C) was expected to diminish the surfactant actions of SPLUNC1 given its proximity 
to α4, while M2 (A48C+V253C), distant from α4, was expected to serve as a control 
(Figures 1, 3; Table 1). The M2 and M3 SPLUNC1 variants were expressed recombinantly 
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in E. coli and purified to homogeneity, and then the structures of each were determined by x-
ray crystallography to 2.6 and 2.5 Å resolution, respectively (Table 2). 31–33 Even in the 
initial electron density maps obtained after molecular replacement, the novel disulfides 
designed into each protein variant were evident. Upon refinement, the M2 (A48C+V253C) 
and M3 (I76C+V214C) designed disulfides were confirmed in the final models (Figure 3A 
and 3B).
We first confirmed that the native disulfide in SPLUNC1 did not contribute to the protein’s 
surfactant activities. A mutant form of human SPLUNC1 in which this native disulfide was 
eliminated (C180A+C224A) exhibited the same surface tension of 38.5 mN/m as wild-type 
SPLUNC1 in a Wilhelmy plate assay (Figure 3C; all proteins at 2 μM). The M2 form of 
SPLUNC1 gave a surface tension of 40 mN/m while the M3 mutant significantly diminished 
surfactant activity, with a reduction of surface tension to only 44 mN/m (Figure 3C). Thus, 
locking α3 and α5 together with a disulfide impacts the surfactant action of this human 
protein. Addition of the reducing agent dithiothreitol (DTT) to the M3 mutant of human 
SPLUNC1 returned the protein to its wild-type surfactant activity (Figure 3C). Combining 
M3 with LAx4 produced a small reduction in SPLUNC1’s surfactant activity: LAx4 is 45.5 
mN/m (Figure 2B), while M3+LAx4 is 47 mN/m (Figure 3C). Upon DTT addition to 
M3+LAx4, reduction of the M3 disulfide bond only eliminated the small M3 contribution 
and left the protein with the 45.5 mN/m value expected for LAx4 alone Figure 3C). Thus, a 
disulfide at the α5 and α-3 interface reduced the surfactant actions of SPLUNC1 beyond 
what eliminating critical leucines near α4 achieved.
These observations were confirmed using contact angle measurements. SPLUNC1 and 
native disulfide-eliminated (C180A+C224A) SPLUNC1 exhibited wetting contact angles of 
86° and 87°, respectively, similar to the M2 disulfide mutant at 86° (Figure 3D). M3 showed 
a slightly wetting contact angle of 88° in this assay. However, combining M3 with LAx4 
produced a non-wetting contact angle of 96° (Figure 3D), higher than the contact angle of 
93° measured for LAx4 alone (Figure 2C). Taken together, these results pinpoint the 
molecular features of human SPLUNC1 necessary for its surfactant activity and further 
support the conclusion that SPLUNC1 employs the α4-adjacent leucines and the 
disassociation of α5 and α-2–3 interface to lower fluid surface tension.
Impact of SPLUNC1 Variants on Airway Surface Liquid and LPS Binding
We assessed biophysically the following proteins as representative of the total panel 
examined above: SPLUNC1, Δα4, LAx4, M3, and LAx4+M3. We first examined the 
melting temperatures (Tm) using CD-monitored unfolding at increasing temperatures. 30 
SPLUNC1 did not unfold even at 95 °C in the absence of reducing agent; upon the addition 
of 5 mM fresh DTT, SPLUNC1 exhibited a Tm of 84 °C. For comparison, the C180A
+C224A native disulfide mutant SPLUNC1 demonstrated a relatively close Tm of 79 °C 
both with and without DTT. The remaining SPLUNC1 variants were all tested with 5 mM 
fresh DTT and exhibited the following values: >95 °C for Δα4, 84 °C for LAx4, 85 °C for 
M3, and 83 °C for for LAx4+M3. In addition, CD spectra of these mutants showed no 
differences in secondary structure relative to SPLUNC1. Thus, the SPLUNC1 variants 
examined do not differ from the native protein in overall structure or stability based on Tm 
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values or secondary structure, with the exception of the Δα4 which does not unfold up to 
95 °C in these conditions. However, Δα4 SPLUNC1 stability was not decreased relative to 
SPLUNC1, indicating that using this protein reagent in subsequent studies would produce 
data not clouded by instability.
We studied a set of human SPLUNC1 variants for their ability to control airway surface 
liquid height in cultured human bronchial airway epithelial cell cultures (HBECs), an 
established function of SPLUNC1. 6 SPLUNC1 maintains airway surface liquid (ASL) 
height in HBECs grown at the air-water interface (Figure 4A). The Δα4 and LAx4 forms of 
human SPLUNC1, which were deficient in surfactant activity, also maintained ASL at a 
level significantly above vehicle (Figure 4A). The M3 disulfide form of SPLUNC1 exhibited 
a slightly reduced ability to regulate ASL, but the LAx4+M3 form of SPLUNC1 recovers 
the ability to maintain ASL (Figure 4A). Together, these data indicate that mutations that 
diminish the surfactant activities of human SPLUNC1 do not impact the ability of this factor 
to control ASL.
We also examined this set of SPLUNC1 variants for their ability to bind to LPS from P. 
aeruginosa and E. coli (Figure 4B, 4C).12 We found that the forms of SPLUNC1 that exhibit 
wild-type surfactant activities (SPLUNC1, ΔS18, LAx5, and M2) all were able to bind to 
LPS either from either of these Gram-negative organisms. By contrast, the four forms of 
SPLUNC1 found to be deficient in surfactant activity (i.e., Δα4, M3, LAx4, and M3+LAx4) 
were all significantly reduced in binding to both forms of LPS (Figure 4B, 4C). Therefore, 
we conclude that SPLUNC1’s LPS binding is functionally linked to its surfactant activity.
SPLUNC1 Variants Against Gram-Negative Bacteria
We next examined the ability of native and variant SPLUNC1 proteins to act as antibiofilm 
and bacteriostatic factors against the cultured airway-relevant bacteria Staphylococcus 
aureus, Pseudomonas aeruginosa and Burkholderia cepacia complex. SPLUNC1 has 
previously been shown to act as an innate antibacterial agent against Gram-negative 
bacteria. 7,8 As expected, our human SPLUNC1 proteins were ineffective against both 
growth or biofilm formation by the Gram-positive pathogen S. aureus, where growth was 
examined by both optical density (OD) and colony forming units (CFU) and biofilm was 
assessed using the crystal violet assay (not shown).
SPLUNC1 and its designed mutants were found to have no effect by OD (Figure 5A) but did 
exert effects by CFU when measuring the growth of the Gram-negative pathogen P. 
aeruginosa (Figure 5B). Specifically, native SPLUNC1 at 10–100 μg/mL significantly 
reduced P. aeruginosa growth, and a similar result was observed with LAx4 SPLUNC1 
(Figure 5B). Δα4 SPLUNC1 showed no effect on P. aeruginosa growth, while both the M3 
and LAx4+M3 SPLUNC1 variants demonstrated enhanced P. aeruginosa anti-growth 
activity starting even at 1 μg/mL (Figure 7B). We conclude that α4 is necessary for the 
bacteriostatic activity of SPLUNC1 against P. aeruginosa, and that the M3 variant is capable 
of improving this activity. While the optical density (OD) measurements did not reveal 
changes in bacterial growth with SPLUNC1, the CFU assay, which depends on growth, 
clearly delineated specific SPLUNC1 effects with P. aeruginosa. All forms of SPLUNC1 
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showed essentially the same anti-biofilm activity against this Gram-negative pathogen, 
reducing biofilm biomass starting at 1–3 μg/mL (Figure 5C).
SPLUNC1 exerted a bacteriostatic effect in both the OD and CFU assays starting at 10 
μg/mL against B. cepacia (Figure 6A). By contrast, all SPLUNC1 mutants exhibited 
diminished bacteriostatic activities in the OD assay, showing either no effect up to 100 
μg/mL for Δα4 SPLUNC1, or effects only at 100 μg/mL for LAx4 and LAx4+M3 
SPLUNC1 (Figure 6A). By CFU, native SPLUNC1, M3 and LAx4+M3 SPLUNC1s showed 
bacteriostatic activity at concentrations equal to or greater than 10 μg/mL, while the Δα4 and 
LAx4 forms of SPLUNC1 exhibited significantly diminished bacteriostatic activity against 
B. cepacia complex (Figure 6B). Similar to the trend observed for P. aeruginosa, native 
SPLUNC1 and all variant forms of SPLUNC1 examined demonstrated significant reduction 
in biofilm formation starting at 10 μg/mL (Figure 6C). Therefore, these results support the 
conclusion that the surfactant activity of SPLUNC1 is important for the bacteriostatic 
activity of this protein against Gram-negative bacteria, but is not involved in its anti-biofilm 
effects on either of the pulmonary pathogens P. aeruginosa or B. cepacia.
Enhanced Antibiofilm Functions Against Gram-Positive S. aureus
Finally, we noted that the mutants examined above had not impacted the antibiofilm 
functions of SPLUNC1 (Figs. 5C, 6C). Thus, we sought to explore that aspect of the 
protein’s activity using a unique set of protein derived from the following observation: the 
GL-rich region between residues 58 and 88 (α1-α4) in the mammalian SPLUNC1s are 
highly similar in sequence, with the noted exception of the water mammals (e.g., the 
SPLUNC1s from dolphin, orca and manatee; Fig. 7A). The SPLUNC1s from land mammals 
are neutral in this area, while the SPLUNC1 orthologs in the water mammals place charged 
amino acids in this region, particularly three anionic residues E62, D63 and D66 (Fig. 7A). 
To test the potential importance of this region toward SPLUNC1 function, we created two 
novel mutant forms of human SPLUNC1: D1 (G58A, S61A, G62E, G63D, G66D, I67T), 
and Dolphinized SPLUNC1, with the full 58-88 region of dolphin SPLUNC1 in place of the 
58-88 region of human SPLUNC1 (Fig. 7A). The crystal structure of D1 SPLUNC1 was 
determined to 2.6 Å resolution (Table 2) and revealed the addition of a significant 
electronegative patch on the protein’s surface, created by the three anionic residues (Fig. 
7A). We examined D1 and Dolphinized SPLUNC1 proteins in bacteriostatic and antibiofilm 
assays with S. aureus, P. aeruginosa and BCC. For the latter two species, the proteins acted 
like native human SPLUNC1 (not shown). For S. aureus, however, while the effect on S. 
aureus growth was similar to SPLUNC1 and remained unchanged, we found that both D1 
and Dolphinized SPLUNC1 exhibited antibiofilm activity above 30 μg/mL protein 
concentration (Fig. 7B, C). Thus, the addition of negatively charged residues in the α1-α4 
region of SPLUNC1 reduced levels of S. aureus biofilm, and highlights this region of the 
protein as important for antibiofilm activity, at least against a Gram-positive bacterium.
DISCUSSION
The abundantly secreted humoral pulmonary factor SPLUNC1 is multifunctional, with 
established roles in regulating ASL volume, as a surfactant in lowering the surface tension at 
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the air-water interface, and as an innate antimicrobial protein against Gram-negative 
bacteria. 4,7,8,38 We hypothesized that specific molecular features of human SPLUNC1 
would be responsible for each function, and we tested this hypothesis by creating site-
specific mutations in the protein and determining their effects on ASL, surfactant, and 
antimicrobial functions. Structural comparisons between human SPLUNC1, equine latherin 
and Dermatophagoides pteronyssinus derP7 reveal similarities in their overall “super-roll” 
fold but differences in the region around SPLUNC1’s α4. Equine latherin, whose structure 
was resolved by NMR in 2013, contains a leucine-rich loop in the area where SPLUNC1 
places its α4, and this L-rich region was proposed by Vance et al. to be crucial for latherin’s 
surfactant activities by bringing the protein to the air-water interface. 28 DerP7 also contains 
isoleucine and leucine residues in the same area (I62, I64, I65, L67). 29
Because SPLUNC1’s α4 region also contains several leucine residues, we chose to test the 
latherin hypothesis by eliminating SPLUNC1’s α4, and by making specific leucine-to-
alanine and leucine-to-serine mutations in this area (LAx4, LSx4). Our results both with 
Wilhelmy plate and contact angle methods support the conclusion that α4 and the leucines in 
that region are crucial for SPLUNC1’s surfactant activities (Figs. 2B–C). Thus, we suggest 
that the α4 and L’s in that region “seed” SPLUNC1’s localization to the air-water interface. 
We term this area of human SPLUNC1 the “L-Loop”. A model of the α4 region extended 
from the body of SPLUNC1 is shown in Figure 8 and reveals that the largely conserved 
leucines 87–88 and 91–92 can be placed at the terminus of a long tether composed of 
flexible and conserved glycine residues, and suggests a L-Loop seeding mechanism for 
SPLUNC1. Liu et al. previously showed that SPLUNC1 expression reduces the surface 
tension of epithelial secretions from human bronchial epithelial cell cultures, and 
furthermore that the level of SPLUNC1 expression correlates with reduction of that surface 
tension. 13
Vance et al. proposed equine latherin an unrolling at the air-water interface to expose the 
hydrophobic core of this protein. 28 We also tested this prediction in human SPLUNC1 by 
engineering disulfide bonds designed to lock together the α1-α6 and α3-α5 secondary 
structural elements of SPLUNC1 in oxidizing conditions (see Fig. 1B). We conclude that the 
two different types of mutants examined here (e.g., M3 and LAx4) reveal two distinct 
mechanisms used by SPLUNC1 to reduce surface tension. First, we propose that the α4 
region unwinds to position the leucines of the L-Loop at the air-water interface (Fig. 4), and 
second that the super-roll fold partially unrolls to expose a portion of the leucine-rich 
hydrophobic core of SPLUNC1 to air. Together, these mechanisms work in concert to 
provide SPLUNC1 with potent surfactant activities, on par with the complex lipid-protein 
mixture CuroSurf.
To further examine our over-arching hypothesis that different regions of SPLUNC1 impart 
distinct functions, we tested the impact these surfactant mutations have on the ability of 
SPLUNC1 to control the airway surface liquid (ASL) levels in cultured human bronchial 
epithelial cells. It has been established previously that the N-terminal S18 region of 
SPLUNC1 inhibits the epithelium sodium channel (ENaC), reducing the influx of sodium 
and water into pulmonary epithelial cells and maintaining the height of the airway surface 
liquid. 5,6 We found that the Δα4, LAx4 and M3+LAx4 forms of human SPLUNC1 were not 
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significantly different from SPLUNC1 in ASL height (Fig. 4A). By contrast, the M3 form of 
SPLUNC1 exhibited a reduced ability to regulate airway liquid height, although this effect 
was not maintained in the M3+LAx4 SPLUNC1 variant (Fig. 4A). These data support the 
conclusion that the presentation of the S18 region of SPLUNC1 to ENaC, which has been 
shown to be impacted by the body of the SPLUNC1 protein, is not eliminated by mutations 
to the protein that affect its surfactant activity. Therefore, it appears that the ENaC-
regulatory and surfactant motifs of SPLUNC1 are both physically and functionally distinct.
However, we found that surfactant activities of SPLUNC1 were required for LPS binding by 
the protein, as mutants that lack surface tension-lowering activities were deficient in LPS 
binding (Figs. 4B, 5C). We conclude that, while the ASL- and surfactant-regulating regions 
of SPLUNC1 are distinct, the LPS-binding and surfactant-regulating regions overlap and are 
functionally related. We propose that LPS molecules bind to SPLUNC1 at the air-water 
interface in a cleft that can form between helices 2 and 5 in Figure 4; access to this cleft 
would be expected to be significantly reduced in the surfactant-deficient variants Δα4, and 
M3+/−LAx4.
We examined SPLUNC1’s impact on growth and biofilm formation by the Gram-positive 
bacterium Staphylococcus aureus and the Gram-negative microbes Pseudomonas aeruginosa 
and Burkholderia cepacia. We found that SPLUNC1 and surfactant mutants had no effect on 
S. aureus. However, SPLUNC1 exerted a bacteriostatic effect on both P. aeruginosa and B. 
cepacia at 10 μg/mL over 24 hours. Furthermore, human SPLUNC1 inhibited biofilm 
formation by P. aeruginosa and B. cepacia at 1 μg/mL and 10 μg/mL, respectively. The 
effects on Pseudomonas growth and biofilm had been reported previously 16,18,20,21,23,39, 
but this provides an important advance on the effects of SPLUNC1 on Burkholderia. These 
data establish that SPLUNC1 contains innate antibacterial activities against two Gram-
negative pulmonary pathogens of the Proteobacteria phylum. We found that our surfactant-
reducing mutations had no effect on anti-biofilm activity against P. aeruginosa and B. 
cepacia. Thus, we conclude that anti-biofilm activity of SPLUNC1 is independent of the α4 
region.
In contrast to the biofilm results, we found that the α4 region of SPLUNC1 was necessary 
for the protein to reduce the growth of P. aeruginosa and B. cepacia. For P. aeruginosa, it has 
been shown previously that SPLUNC1 binds to this bacterium and produces holes in its 
outer membrane; together, these actions are expected to impact bacterial growth. 23 Δα4-
SPLUNC1 may lack one or both of these functions, leading to its loss of bacteriostatic 
activity, and it is attractive to speculate that the leucine-rich α4 of SPLUNC1 may serve as 
the pore-forming “warhead” of this protein toward Gram-negative pathogens. An alternative 
hypothesis is that, because Δα4-SPLUNC1 lacks wild-type surfactant abilities, this protein 
variant is unable to spread bacteria at the air-water interface to prevent growth. However, the 
data outlined below for other SPLUNC1 variants with reduced surfactant activities makes 
this hypothesis less likely, as they show differential effects depending on the mutation and 
the bacterial species tested.
Indeed, we find for P. aeruginosa that the M3 and M3+LAx4 forms of SPLUNC1 exhibits 
enhances bacteriostatic activity by 10-fold over SPLUNC1; both M3-containing SPLUNC1s 
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significantly reduces P. aeruginosa growth at 1 μg/mL, while the native protein exerts this 
effect at 10 μg/mL. We speculate that the M3 disulfide bond may restrict the conformation 
of the L-Loop region of SPLUNC1 in a manner that enhances the protein’s ability to bind to 
or form pores in Gram-negative bacteria, leading to enhanced bacteriostatic effects. Future 
studies will focus on testing these predictions. However, because the LAx4 form of 
SPLUNC1, which is also deficient in surfactant activity, does not exhibit a difference in P. 
aeruginosa bacteriostatic effects, we conclude that the inherent surface tension-lowering 
qualities of SPLUNC1 are not responsible for its ability to reduce bacterial growth. 
Interestingly, however, for B. cepacia the Δα4 and LAx4 forms of SPLUNC1 were 
significantly diminished in their bacteriostatic activities, while the M3 and M3+LAx4 
SPLUNC1s were closer to native SPLUNC1. These results indicate that there are unique 
features between these two Proteobacterial pathogens that lead to differential effects by the 
same forms of SPLUNC1. Future studies will be undertaken to determine how different 
SPLUNC1s exert alternative effects on different Gram-negative bacteria.
Because the surfactant mutants had no effect on the antibiofilm activities of SPLUNC1, we 
probed the SPLUNC1s that were most sequence divergent in the α1-α4 region, those of the 
water mammals. These forms of the protein encode anionic residues in the 58–68 region in 
place of the neutral side chains maintained by the land mammals. Thus, we hypothesized 
that a variant human SPLUNC1 with these residues would exhibit a distinct function. 
Indeed, we found that inclusion of just six amino acid changes (D1 SPLUNC1) was 
sufficient to impart antibiofilm activity toward the Gram-positive pathogen S. aureus, albeit 
via an enigmatic mechanism given the anionic character of the S. aureus cell envelop. 40 
Still, these results highlight the importance of this α1-α4 region in the antibiofilm activity of 
SPLUNC1, at least toward Gram-positive microbes, and suggest that additional protein 
variants may be created that further improve their effects against S. aureus and other 
bacterial pathogens.
Taken as a whole, the data presented define for the first time the molecular foundations of 
human SPLUNC1’s ability to act as a surfactant and antimicrobial factor. The L-Loop and 
α4 regions appear essential for surfactant, LPS-binding, and bacteriostatic activities, and 
each of these functions is distinguishable from the ASL-regulating actions of SPLUNC1, 
indicating that this multifunctional protein has multiple functional sites. Furthermore, 
because enhanced antibacterial actions were observed for specific forms of SPLUNC1 (e.g., 
M3, LAx4) that lack statistically significant effects on regulating ASL height, it appears that 
SPLUNC1s with improved antimicrobial actions could successfully be designed. With 
development, such reagents have the potential to be employed as prophylactics to prevent 
infections by opportunistic pulmonary pathogens in at-risk patient populations, such as those 
with cystic fibrosis, chronic obstructive pulmonary disorder, or are immune compromised.
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ABBREVIATIONS
LPS Lipopolysaccharide
SPLUNC1 Short Palate Lung Nasal Epithelial Clone 1
ENaC epithelial sodium channel
CF cystic fibrosis
DPPC dipalmitoylphosphatidylcholine
LBP lipopolysaccharide binding protein
BPI bacteriocidal permeability-increasing protein
CD circular dichroism
Δα4 SPLUNC1 lacking α4
LAx4 leucines L87, L88, L91, L92 simultaneously mutated to alanines
LSx4 leucines L87, L88, L91, L92 simultaneously mutated to serine
LAx5 surface-exposed leucines L191, L192, L195, L203, L204 located away from 
α4 on human SPLUNC1 simultaneously mutated to alanine
M2 A48C+V253C SPLUNC1
M3 I76C+V214C SPLUNC1
DTT dithiothreitol
Tm melting temperatures
HBECs human bronchial airway epithelial cell cultures
ASL airway surface liquid
OD optical density
CFU colony forming units
D1 human SPUNC1 with five Dolphin SPLUNC1 mutations [G58A, S61A, 
G62E, G63D, G66D, I67T]
BCC Burkholderia cenocepacia complex.
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Figure 1. Structural Features of Human SPLUNC1
A. N- and C- termini are indicated (gray) as are the secondary structural elements (blue, 
green). The native disulfide bond is shown and labeled, and the amino acid positions used to 
create the two novel disulfides presented here are indicated in cyan (48, 253 for M2) and 
magenta (76, 214 for M3). B. Secondary structural elements are shown in schematic, as are 
the locations of the native disulfide and two novel disulfides presented (M2, M3). In 
addition, a schematic view of the Δα4 mutant is indicated (orange), and the locations of the 
Leu-Ala or -Ser mutations in the LAx4 and LSx4 variants are also shown (red). The location 
of the five Leu-Ala changes in the control LAx5 mutation is also shown (black). Finally, the 
gray dotted line indicates secondary structural elements that may disassociate during a 
potential “unrolling” of the SPLUNC1 super-roll fold. C. Human SPLUNC1-equine 
Latherin superposition with the sequences of each protein in the α4 region of human 
SPLUNC1 also shown, and hydrophobic Latherin residues highlighted in bold. The Δα4 
mutant of SPLUNC1 is indicated with dotted line. D. Human SPLUNC1-dust mite derP7 
superposition with the sequences of each protein in the α4 region of human SPLUNC1 also 
shown, and hydrophobic derP7 residues highlighted in bold. The Δα4 mutant of SPLUNC1 
is indicated with dotted line.
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Figure 2. SPLUNC1Surfactant Activity
A. Surface tension was measured using the Wilhelmy plate method for the indicated proteins 
or other solutions at the indicated concentrations. B. Surfactant Activities of SPLUNC1 
Variants. SPLUNC1, as well as the Δ18 and LAx5 SPLUNC1 variants, reduce surface 
tension using the Wilhelmy plate method to ~39 mN/m, while the LSx4, LAx4 and Δα4 
forms of SPLUNC1 are relatively deficient in surfactant activity and only reduce surface 
tension to ~46 mN/m. All proteins at 2 μM. C. Surfactant Activity by Contact Angle of 
SPLUNC1 and other Solutions. The same SPLUNC1 proteins shown in panel B to be 
optimal surfactant are “wetting” (contact angle <90°) in their actions in this contact angle 
assay, while the LSx4, LAx4 and Δα4 forms of SPLUNC1, as well as BSA and buffer, are 
“non-wetting” (contact angle >90°). All proteins at 2 μM. For all data in this figure, 
experiments were performed ten times, and means ± SEM are shown.
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Figure 3. Designed SPLUNC1 Disulfide Mutants
A. Crystal Structure of M2 SPLUNC1. Overall 2.6 Å resolution structure and 2|Fo−Fc| 
electron density contoured at 1.5σ for designed M2 disulfide bond. B. Crystal Structure of 
M3 SPLUNC1. Overall 2.54 Å resolution structure and 2|Fo−Fc| electron density contoured 
at 1.5σ for designed M3 disulfide bond. C. Surface Tension for Disulfide SPLUNC1 
Mutants. The M2 mutant and SPLUNC1 with the native disulfide eliminated (C180A/
C224A) show surface tension by Wilhelmy plate close to native SPLUNC1, ~38 mN/m, 
while the M3 and M3+LAx4 mutants exhibit relatively deficient surfactant activity, with 
surface tensions >44 mN/m. Additional of DTT reduced surface tension of the M3 mutant 
back to 38 mN/m, but did not impact M3+LAx4, which exhibited the surface tension 
expected for LAx4 alone (see Fig. 2B). All proteins at 2 μM. D. Surfactant Activity by 
Contact Angle for Disulfide Mutants. Most SPLUNC1 proteins are “wetting” (contact angle 
<90°) in their actions in this contact angle assay, while the M3+LAx4 form of SPLUNC1, as 
well as BSA and buffer, are “non-wetting” (contact angle >90°). All proteins at 2 μM. For all 
data in this figure, experiments were performed ten times, and means ± SEM are shown.
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Figure 4. Impact of SPLUNC1 Variants on ASL and on LPS Binding
A. Indicated SPLUNC1 proteins were tested for their impact on airway surface liquid (ASL) 
levels above cultured human airway epithelial cell cultures. B. SPLUNC1 Binding to 
Pseudomonas LPS as assessed by ELISA. C. SPLUNC1 Binding to E. coli LPS as assessed 
by ELISA.
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Figure 5. SPLUNC1 Variants as Antimicrobial Agents against against Pseudomonas aeruginosa
A. The indicated SPLUNC1 variants tested at listed concentrations had no impact on this 
measure of P. aeruginosa growth as measured by OD600nm. B. All SPLUNC1 variants tested, 
except for Δα4, significantly reduced P. aeruginosa growth as measured by colony forming 
units (CFU). **, p<0.01. C. All SPLUNC1 variants tested significantly reduced P. 
aeruginosa biofilm formation. **, p<0.01.
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Figure 6. SPLUNC1 Variants as Antimicrobial Agents against against Burkholderia cenocepacia 
complex (BCC)
A. All SPLUNC1 variants tested, except for Δα4, significantly reduced BCC growth as 
measured by OD600 nm. **, p<0.01. B. All SPLUNC1 variants tested, except for Δα4 and 
LAx4, significantly reduced BCC growth as measured by colony forming units (CFU). *, 
p<0.05; **, p<0.01. C. All SPLUNC1 variants tested significantly reduced BCC biofilm 
formation. **, p<0.01.
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Figure 7. Human SPLUNC1 with Mutations from Dolphin SPLUNC1
A. Surface of human SPLUNC1 D1 Mutant of Human SPLUNC1 with Indicated Mutations. 
Six mutations were introduced and led to a marked increase in negative charge on the 
protein surface. The sequences of human and dolphin SPLUNC1s are indicated, with 
mutations that form D1 and Dolphinized SPLUNC1s indicated. B. The SPLUNC1 variants 
tested did not impact S. aureus growth by OD600 nm. C. Both Dolphinized and D1 
SPLUNC1s significantly reduced biofilm generation by S. aureus. **, p<0.01.
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Figure 8. Model for Human SPLUNC1 with Extended α4 Region
Largely conserved glycine (yellow) and leucines (red) in mammalian SPLUNC1 sequences 
are shown. This flexible region can be modeled to present the key leucines examined here to 
the air-water interface to break fluid surface tension.
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Table 1
SPLUNC1 Variants Examined
Name Amino Acids Function Notes
SPLUNC1 20-256 See reference 6
ΔS18 45-256 See reference 6
Δα4 20-256 with
Δ76-105
• Reduced surfactant activity
• Reduced LPS binding
• Reduced bacteriostatic activity against P. 
aeruginosa and B. cepacia
77-105 replaced with 
GSGS
LAx4 (LSx4) 20-256 with
L87A (L87S)
L88A (L88S)
L91A (L91S)
L92A (L92S)
• Reduced surfactant activity
• Reduced LPS binding
• Reduced bacteriostatic activity against B. 
cepacia
LAx5 20-256 with
L191A
L192A
L195A
L203A
L204A
C180A/C224A 20-256 with
C180A
C224A
M2 20-256 with
A48C
V253C
M3 20-256 with
I76C
V214C
• Reduced surfactant activity
• Reduced LPS binding
M3+ LAx4 20-256 with both M3 and LAx4 • Reduced surfactant activity
• Reduced LPS binding
Dolphinized 20-256 with
Δ58-88
• Increased antibiofilm activity against S. aureus 58-88 replaced with 
equivalent residues from 
dolphin SPLUNC1; see 
Fig. 7A
D1 20-256 with
G58A
S61A
G62E
G63D
G66D
I67T
• Increased antibiofilm activity against S. aureus See Fig. 7A
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Table 2
Crystallographic Statistics for SPLUNC1 Variant Structures
M2 M3 D1
Resolution (highest shell), Å 38.8–2.60 (2.69–2.60) 28.3–2.54 (2.63–2.54) 29.6–2.55 (2.64–2.55)
Space group C2221 C2221 C2221
Unit Cell, Å 47.1, 203.6, 120.2 47.8, 206.2, 117.6 48.0, 204.9, 118.7
Total reflections (F>0) 94111 68073 67696
Unique reflections 18284 19395 19300
Multiplicity 5.1 (5.1) 3.5 (3.4) 3.5 (3.2)
Completeness, % 99.6 (96.7) 98.7 (94.5) 98.7 (89.4)
Mean I/sigma(I) 21.3 (4.34) 14.5 (2.3) 13.8 (2.1)
Wilson B-factor, Å2 57.6 58.95 54.92
Rmerge 0.062 (0.580) 0.055 (0.71) 0.057 (0.657)
R 0.2198 0.1995 0.2122
Rfree 0.2837 0.2677 0.2744
No. of atoms per AU:
protein, water 2933, 17 2934, 13 3005, 33
rms bonds, Å 0.009 0.010 0.009
rms angles,° 1.51 1.48 1.50
Ramachandran favored, % 89 93 92
Ramachandran outliers, % 3.4 3 2
Clash score 15.61 11 11
Average B-factor, Å2 67 70.2 65
RCSB ID 517L 517J 517K
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